Prigent Kevin, Aide Nicolas
Nuclear Medicine Department, University Hospital, Caen, France; Service de Médecine Nucléaire, CHU de CAEN, Avenue Côte de Nacre, Caen, France.
Service de Médecine Nucléaire, CHU de CAEN, Avenue Côte de Nacre, Caen, France; University of Normandy, France.
PET Clin. 2020 Jan;15(1):1-10. doi: 10.1016/j.cpet.2019.08.006.
After a short summary of the biological basis of the immune checkpoint inhibitors used for the treatment of nonhematologic solid tumors, the issues of pseudoprogression, hyperprogression, and immune-related side effects are discussed as well as their implications for patient management. Recommendations are provided for performing F-Fludeoxyglucose PET scanning, assessing tumor response, and reporting immune-related side effects, with representative clinical cases.
在简要总结用于治疗非血液系统实体瘤的免疫检查点抑制剂的生物学基础后,讨论了假性进展、超进展和免疫相关副作用的问题及其对患者管理的影响。还提供了关于进行氟代脱氧葡萄糖正电子发射断层扫描(F-FDG PET)、评估肿瘤反应以及报告免疫相关副作用的建议,并列举了代表性临床病例。